Axsome Therapeutics, Inc.
AXSM
$148.58
$0.770.52%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 13.96% | 23.53% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.96% | 23.53% | |||
| Cost of Revenue | -11.42% | 37.38% | |||
| Gross Profit | 16.46% | 22.31% | |||
| SG&A Expenses | 15.32% | 7.86% | |||
| Depreciation & Amortization | 1.13% | 1.08% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.65% | 10.13% | |||
| Operating Income | 26.54% | 19.21% | |||
| Income Before Tax | 3.48% | 17.64% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 1.55% | 19.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.55% | 19.26% | |||
| EBIT | 26.54% | 19.21% | |||
| EBITDA | 27.63% | 19.80% | |||
| EPS Basic | 2.69% | 20.19% | |||
| Normalized Basic EPS | 27.86% | 20.36% | |||
| EPS Diluted | 2.69% | 20.47% | |||
| Normalized Diluted EPS | 27.86% | 20.36% | |||
| Average Basic Shares Outstanding | 1.17% | 1.17% | |||
| Average Diluted Shares Outstanding | 1.17% | 1.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||